Clinical Trial

Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN). ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due to small fiber neuropathy (SFN).
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-05-12; most recent amendment 2026-05-28.
Status change: Not Yet Recruiting → Recruiting 2025-10-09
Trial Details
NCT Number NCT06980948
Lead Sponsor Sangamo Therapeutics
Conditions Chronic Neuropathic Pain
Enrollment 27 participants
Start Date 2025-12-04
Primary Completion 2027-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-01